776,082 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Bought by Driehaus Capital Management LLC

Driehaus Capital Management LLC acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 776,082 shares of the company’s stock, valued at approximately $4,788,000. Driehaus Capital Management LLC owned about 1.37% of Design Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in Design Therapeutics during the fourth quarter worth about $249,000. Northern Trust Corp boosted its stake in shares of Design Therapeutics by 15.2% in the 4th quarter. Northern Trust Corp now owns 388,125 shares of the company’s stock worth $2,395,000 after buying an additional 51,351 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Design Therapeutics by 60.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 215,265 shares of the company’s stock valued at $1,328,000 after acquiring an additional 80,905 shares in the last quarter. Walleye Capital LLC increased its position in shares of Design Therapeutics by 101.6% during the fourth quarter. Walleye Capital LLC now owns 141,127 shares of the company’s stock valued at $871,000 after acquiring an additional 71,127 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Design Therapeutics during the fourth quarter worth $299,000. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN opened at $3.49 on Friday. The company has a market capitalization of $198.10 million, a PE ratio of -4.11 and a beta of 1.77. Design Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $7.77. The business has a fifty day moving average price of $4.04 and a two-hundred day moving average price of $4.96.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Sell-side analysts anticipate that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.